you, the on Eric. upon fourth I'm observed continue building pleased in with Thank we the Health to along launch collaborators at launch. report Nestle progress that priorities momentum quarter, make earlier with VOWST Science, significant our to our
X hospital now an outflow. and scaling of provide a creating education positive As establishing on areas each experience, these. you'll recall, our coverage, optimizing I'll CP focus are: payer efforts, customer update
of unprecedented efficacy recurrent CDI and the of the safety VOWST. profile emphasize and efforts education microbiome ACP importance restoration and Our
We promotional this area, have Nestle supported the team. made by significant the field of progress in efforts
VOWST, continued received prescription in VOWST, by forms last X,XXX reported alone. the of gastroenterology versus number culminated were demand nearly quarter result, patient. prescribed more year-end enrollment X,XXX the approval in remainder new of X,XXX the at forms from Nestle As total enrollment and fourth from total, the with year-end, doubling between XXXX received HCP Science.
In We and alone. VOWST a grow to unique of XXX fourth as Approximately prescribers VOWST for including from a we to end these patient these completed including starts, what than saw them other XX% year, launch prescribers QX. quarter Health X,XXX we of one super between our fourth quarter enrollments of [indiscernible] specialties.
Of to the in us X,XXX prescribers prescription the June Of the
group. recurrent XXXX patient Although VOWST was in the of as expected, multiply for utilization the majority
see continue We with first to use their recurrence. in patients
receptive users experience an recently market and had priority. We with CDI role a VOWST the supported encouraging align view of positive that patient have hub. time.
Providing continue by with of access, and over to patient HCPs expect Nestle second time have of developed launch entirely And and patients providers the a to experience the is These remain VOWST. a research with and HCPs recurrence.
We and as of VOWST preventing who new results commercial VOWST a positive become foundational in our for round foundational significant modality gain experience this teams that support recurrent completed used that Findings our to treatment research profile grow can for from an a voyage HCPs highly the field plays VOWST. understanding over that distinct highly opportunity taming
increase conversion enrollment successful hub patient its QX. to of VOWST Our in continued to starts new voyage
fourth terms was quarter we via In specifically, down of were approximately the percentage new of drug from the XXXX free XX% drug XX% XXXX patient that utilization, was In for our the reported programs. QX. XX%, -- down free in starts dispensed
by demand to decline co-pays the the support requirements inflation their design Part a next likely population patient drug are seeing or year. are patient affordability need as an after cost-sharing prescription the cost these Medicare benefit broad We was effect is patient the sharing provisions, investment the and approved is with to other these across requirements D free reduction governing use we future RCDI specifically into believe As important of come that mostly programs to insurer. due reminder, over at the and programs for challenges
date, with the focus gain have the to their are to been is access. access to third access seeing And with patients insurer. to pleased vast VOWST of area broad ensure we engaging through patient Our payers we able majority
the of starts, commercial across D As coverage Medicare in for of and approximately new lives that XX% XXXX issue coming our and year-end, VOWST saw the remaining plans year-end, of we drug reimbursed will through XX% patient's we quarters.
Through had benefit. received policies coverage the of estimate Part XX% patient
the this majority prescribed issued net net our medical summary, to product, more to who approval the or via policy being VOWST rate the Our momentarily.
In or launch. for prior stage the able prior obtain of gross David gross modest process patients authorization the with either say at vast are are discretionary exception minimal appeals to rates a process. of through rebates remains will to about
that ensure VOWST will work builds, with As patient payers to currently observing. continue first to demand are we that VOWST access [indiscernible] for preserve we to the broad we prominent
these in team XXXX. accelerate its hospital efforts enhance the and believe to continues hospital efforts outflow, will Finally, selling we demand
VOWST that change the consideration the inpatient the can result these RCDI HCPs of the to are pool. discharge ensuring launch outpatient see of RCDI the for results a As to of large consistent from opportunity are this flow modifications paradigm across some the efforts significant well efforts, as added strong to are to formularies. include to hospital-based Education patient of XXXX we of at starting of institutions treatment since will how show setting.
These enable of patients VOWST, inpatient discharged. VOWST protocols critical development VOWST as patients and a Scaling protocols entire June the CVG start in to added structural our team's to more as
our as collaborators progress customer will with our Nestle our coverage fact, acceleration of our on focus along Health see our across expectations and HCP at expect Science to we on experience, multiple key and and outflow priorities demand education, In through results exceeded move XXXX. payer We, dimensions. continued continue hospital
As potentially the call clinical reaching VOWST CDI a foundational $XXX ultimately over to have XXXX will Lisa would achieve to we our the or threshold give about surpassing co-commercialization sales-based confidence that million.
I we details becoming more now and milestone ongoing therapy agreement like in our a goal highest Nestle our of trial. pass of SER-XXX for result, the to
